Publication | Open Access

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Breast OncologyHer2-expressing Breast CancerMedicinePharmacologyTrastuzumab DuocarmazineBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyPhase 1